Drug Information

Drug General Information
Drug ID
D02GWF
Former ID
DNC009514
Drug Name
PACTIMIBE
Drug Type
Small molecular drug
Indication Arteriosclerosis [ICD9: 440; ICD10:I70] Phase 2/3 [521676]
Structure
Download
2D MOL

3D MOL
Formula
C25H40N2O3
Canonical SMILES
CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C
InChI
1S/C25H40N2O3/c1-7-8-9-10-11-12-14-27-15-13-19-17(2)20(16-21(28)29)18(3)22(23(19)27)26-24(30)25(4,5)6/h7-16H2,1-6H3,(H,26,30)(H,28,29)
InChIKey
TXIIZHHIOHVWJD-UHFFFAOYSA-N
PubChem Compound ID
3081927
Target and Pathway
Target(s) Liver carboxylesterase Target Info Inhibitor [529589]
KEGG Pathway Drug metabolism - other enzymes
Metabolic pathways
Pathway Interaction Database E2F transcription factor network
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Heroin metabolism
Irinotecan Pathway
Fluoropyrimidine Activity
Phase I biotransformations, non P450
References
Ref 521676ClinicalTrials.gov (NCT00151788) Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.. U.S. National Institutes of Health.
Ref 529589J Med Chem. 2008 Aug 14;51(15):4823-33. Epub 2008 Jul 12.Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical propertiesand biological activities by introduction of carboxylic acid.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.